GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (CHIX:XVIVOs) » Definitions » Revenue

Xvivo Perfusion AB (CHIX:XVIVOS) Revenue : kr750.6 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Xvivo Perfusion AB Revenue?

Xvivo Perfusion AB's revenue for the three months ended in Sep. 2024 was kr198.5 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was kr750.6 Mil. Xvivo Perfusion AB's Revenue per Share for the three months ended in Sep. 2024 was kr6.26. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was kr24.03.

During the past 12 months, the average Revenue per Share Growth Rate of Xvivo Perfusion AB was 25.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was 44.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was 22.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was 15.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 12 years, Xvivo Perfusion AB's highest 3-Year average Revenue per Share Growth Rate was 44.80% per year. The lowest was 4.40% per year. And the median was 11.50% per year.


Xvivo Perfusion AB Revenue Historical Data

The historical data trend for Xvivo Perfusion AB's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Revenue Chart

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 220.84 179.86 258.39 415.29 597.54

Xvivo Perfusion AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 146.61 155.74 186.02 210.35 198.48

Competitive Comparison of Xvivo Perfusion AB's Revenue

For the Medical Devices subindustry, Xvivo Perfusion AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Revenue distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Revenue falls into.



Xvivo Perfusion AB Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr750.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xvivo Perfusion AB  (CHIX:XVIVOs) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Xvivo Perfusion AB Revenue Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB Business Description

Traded in Other Exchanges
Address
Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB Headlines

No Headlines